National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Etelcalcetide (Parsabiv®)

Etelcalcitide (Parsabiv®) is indicated for the treatment of secondary hyperparathyroidism (SHPT) in adult patients with chronic kidney disease (CKD) on haemodialysis.

Rapid Review Process Complete
Rapid review received 14/06/2017
Rapid review completed 01/09/2017
Rapid Review outcome Full pharmacoeconomic assessment recommended at the submitted price

The HSE has approved reimbursement following confidential price negotiations; April 2018.